JP2018538343A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018538343A5 JP2018538343A5 JP2018532777A JP2018532777A JP2018538343A5 JP 2018538343 A5 JP2018538343 A5 JP 2018538343A5 JP 2018532777 A JP2018532777 A JP 2018532777A JP 2018532777 A JP2018532777 A JP 2018532777A JP 2018538343 A5 JP2018538343 A5 JP 2018538343A5
- Authority
- JP
- Japan
- Prior art keywords
- red blood
- cells
- composition
- cell
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021109883A JP2021155454A (ja) | 2015-12-22 | 2021-07-01 | 赤血球を用いる治療方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2015905309 | 2015-12-22 | ||
| AU2015905309A AU2015905309A0 (en) | 2015-12-22 | Therapeutic methods using erythrocytes | |
| PCT/AU2016/000404 WO2017106899A2 (en) | 2015-12-22 | 2016-12-22 | Therapeutic methods using erythrocytes |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021109883A Division JP2021155454A (ja) | 2015-12-22 | 2021-07-01 | 赤血球を用いる治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018538343A JP2018538343A (ja) | 2018-12-27 |
| JP2018538343A5 true JP2018538343A5 (enExample) | 2020-02-06 |
Family
ID=59088638
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018532777A Pending JP2018538343A (ja) | 2015-12-22 | 2016-12-22 | 赤血球を用いる治療方法 |
| JP2021109883A Pending JP2021155454A (ja) | 2015-12-22 | 2021-07-01 | 赤血球を用いる治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021109883A Pending JP2021155454A (ja) | 2015-12-22 | 2021-07-01 | 赤血球を用いる治療方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11564948B2 (enExample) |
| EP (1) | EP3393482A4 (enExample) |
| JP (2) | JP2018538343A (enExample) |
| KR (1) | KR20180102096A (enExample) |
| CN (1) | CN108883133A (enExample) |
| AU (1) | AU2016374643B2 (enExample) |
| CA (1) | CA3009369A1 (enExample) |
| SG (1) | SG11201805052YA (enExample) |
| WO (1) | WO2017106899A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113337402B (zh) | 2011-10-17 | 2024-11-29 | 麻省理工学院 | 细胞内传递 |
| EP3848695A1 (en) | 2013-08-16 | 2021-07-14 | Massachusetts Institute Of Technology | Selective delivery of material to cells |
| KR20170074235A (ko) | 2014-10-31 | 2017-06-29 | 메사추세츠 인스티튜트 오브 테크놀로지 | 면역 세포로의 생체분자의 전달 |
| CA2964138C (en) | 2014-11-14 | 2023-11-14 | Massachusetts Institute Of Technology | Disruption and field enabled delivery of compounds and compositions into cells |
| US11125739B2 (en) | 2015-01-12 | 2021-09-21 | Massachusetts Institute Of Technology | Gene editing through microfluidic delivery |
| SG10201912910PA (en) | 2015-07-09 | 2020-02-27 | Massachusetts Inst Technology | Delivery of materials to anucleate cells |
| WO2017041051A1 (en) | 2015-09-04 | 2017-03-09 | Sqz Biotechnologies Company | Intracellular delivery of biomolecules to cells comprising a cell wall |
| CN114019171A (zh) | 2015-10-07 | 2022-02-08 | 善威生物私人有限公司 | 血液制备和图谱分析 |
| WO2018112500A1 (en) * | 2016-12-20 | 2018-06-28 | Sangui Bio Pty. Ltd | Blood profiling with protease inhibitors |
| WO2022192446A1 (en) * | 2021-03-10 | 2022-09-15 | Terasaki Institute For Biomedical Innovation | Production of heme for cell-based meat products |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4931276A (en) | 1987-10-30 | 1990-06-05 | Franco Robert S | Method for introducing desired agents into red blood cells |
| US5858358A (en) * | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| WO1992005801A1 (en) | 1990-10-04 | 1992-04-16 | University Of Virginia Alumni Patents Foundation | Primate erythrocyte bound monoclonal antibody heteropolymers |
| FR2778851B1 (fr) * | 1998-05-19 | 2002-07-26 | Aetsrn | Composition a base d'inhibiteurs de cysteine-proteases pour retarder la senescence, l'autodestruction et l'hemolyse des erythrocytes |
| US8431117B2 (en) * | 1999-08-30 | 2013-04-30 | David S Terman | Sickled erythrocytes with anti-tumor agents induce tumor vaso-occlusion and tumoricidal effects |
| MXPA03000765A (es) * | 2000-07-24 | 2004-05-21 | Gendel Ltd | Suministro de polipeptido il-2. |
| PT1495328E (pt) | 2002-04-16 | 2014-09-09 | Vlaams Interuniv Inst Biotech | Um marcador para medir cirrose hepática |
| GB0325483D0 (en) | 2003-10-31 | 2003-12-03 | Plasmacute As | Assay |
| US20080095749A1 (en) * | 2004-03-22 | 2008-04-24 | Sudeepta Aggarwal | Mesenchymal stem cells and uses therefor |
| US7378054B2 (en) | 2004-04-16 | 2008-05-27 | Savvipharm Inc | Specimen collecting, processing and analytical assembly |
| US20060166223A1 (en) | 2005-01-26 | 2006-07-27 | Reed Michael W | DNA purification and analysis on nanoengineered surfaces |
| WO2006123253A2 (en) | 2005-03-29 | 2006-11-23 | Inverness Medical Switzerland Gmbh | Device and method of monitoring a patient |
| US20100184049A1 (en) | 2007-04-27 | 2010-07-22 | Steve Goodison | Glycoprotein Profiling of Bladder Cancer |
| FR2919804B1 (fr) * | 2007-08-08 | 2010-08-27 | Erytech Pharma | Composition et vaccin therapeutique anti-tumoral |
| US20110245092A1 (en) | 2008-03-04 | 2011-10-06 | John Bilello | Diagnosing and monitoring depression disorders based on multiple serum biomarker panels |
| CA3150872A1 (en) * | 2008-05-06 | 2009-11-12 | Astellas Institute For Regenerative Medicine | Methods for producing enucleated erythroid cells derived from pluripotent stem cells |
| WO2010147621A1 (en) | 2009-06-16 | 2010-12-23 | The Trustees Of Columbia University In The City Of New York | Methods for ameliorating adverse effects associated with transfusion of aged red blood cells |
| CN102472744B (zh) | 2009-08-13 | 2015-11-25 | 巴斯夫欧洲公司 | 诊断甲状腺疾病的手段和方法 |
| WO2011091154A2 (en) * | 2010-01-21 | 2011-07-28 | The Regents Of The University Of California | Use of human erythrocytes for prevention and treatment of cancer dissemination and growth |
| WO2011127056A2 (en) | 2010-04-05 | 2011-10-13 | The Uab Research Foundation | Biomarkers for assessing exposure to ionizing radiation and absorbed dose |
| SG195180A1 (en) | 2011-05-31 | 2013-12-30 | Singapore Health Serv Pte Ltd | Method for detecting disease biomarkers |
| BR112013032659B1 (pt) * | 2011-07-06 | 2021-04-06 | Histocell S.L. | Método para o tratamento de células-tronco mesenquimais, que compreende a obtenção e o isolamento das células-tronco mesenquimais e a cultura das células em um meio de tratamento; e uso das células |
| GB201116767D0 (en) * | 2011-09-28 | 2011-11-09 | St George S Hospital Medical School | Treatment for mitrochondrial neurogastrointestinal encephalomyopathy |
| JP6194350B2 (ja) * | 2012-03-21 | 2017-09-06 | エリテック・ファルマ | 急性骨髄性白血病（ａｍｌ）の処置のための薬剤 |
| HU230341B1 (hu) * | 2012-04-20 | 2016-02-29 | Advancell Diagnosztika Kft. | A vörösvérsejt-membrán kvantitatív biomarkerei |
| JP6329537B2 (ja) | 2012-07-11 | 2018-05-23 | サンガモ セラピューティクス， インコーポレイテッド | 生物学的薬剤の送達のための方法および組成物 |
| US10272115B2 (en) * | 2013-03-11 | 2019-04-30 | Taiga Biotechnologies, Inc. | Production and use of red blood cells |
| BR112015028278B1 (pt) * | 2013-05-10 | 2022-12-20 | Erydel S.P.A | Processo para a preparação de eritrócitos carregados com uma ou mais substâncias de interesse farmacêutico, eritrócitos carregados com uma ou mais substâncias de interesse farmacêutico, composição farmacêutica e uso terapêutico dos ditos eritrócitos |
| JP6383920B2 (ja) | 2013-09-11 | 2018-09-05 | 有限会社ピコデバイス | パーキンソン病の判定基準とする方法 |
| US10273455B2 (en) * | 2014-04-07 | 2019-04-30 | Iucf-Hyu | In vitro expansion of erythroid cells |
| CN107735095B (zh) * | 2015-05-18 | 2022-06-14 | 希玛奈克斯特股份有限公司 | 储存全血的方法及其组合物 |
| CN114019171A (zh) | 2015-10-07 | 2022-02-08 | 善威生物私人有限公司 | 血液制备和图谱分析 |
| WO2018112500A1 (en) | 2016-12-20 | 2018-06-28 | Sangui Bio Pty. Ltd | Blood profiling with protease inhibitors |
-
2016
- 2016-12-22 CN CN201680082308.2A patent/CN108883133A/zh active Pending
- 2016-12-22 EP EP16876988.3A patent/EP3393482A4/en not_active Withdrawn
- 2016-12-22 KR KR1020187020347A patent/KR20180102096A/ko not_active Ceased
- 2016-12-22 CA CA3009369A patent/CA3009369A1/en active Pending
- 2016-12-22 WO PCT/AU2016/000404 patent/WO2017106899A2/en not_active Ceased
- 2016-12-22 AU AU2016374643A patent/AU2016374643B2/en active Active
- 2016-12-22 JP JP2018532777A patent/JP2018538343A/ja active Pending
- 2016-12-22 SG SG11201805052YA patent/SG11201805052YA/en unknown
- 2016-12-22 US US16/064,973 patent/US11564948B2/en active Active
-
2021
- 2021-07-01 JP JP2021109883A patent/JP2021155454A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018538343A5 (enExample) | ||
| Lucarini et al. | IL-33 restricts tumor growth and inhibits pulmonary metastasis in melanoma-bearing mice through eosinophils | |
| Gangaplara et al. | Type I interferon signaling attenuates regulatory T cell function in viral infection and in the tumor microenvironment | |
| Figeac et al. | Nanotubular crosstalk with distressed cardiomyocytes stimulates the paracrine repair function of mesenchymal stem cells | |
| Yates et al. | Multipotent stromal cells/mesenchymal stem cells and fibroblasts combine to minimize skin hypertrophic scarring | |
| Lambe et al. | DOCK8 is essential for T‐cell survival and the maintenance of CD8+ T‐cell memory | |
| Strutt et al. | Multipronged CD 4+ T‐cell effector and memory responses cooperate to provide potent immunity against respiratory virus | |
| CA3059634A1 (en) | Combinatorial cancer immunotherapy | |
| JP2017500061A5 (enExample) | ||
| Feng et al. | Ex vivo induced regulatory T cells regulate inflammatory response of Kupffer cells by TGF-beta and attenuate liver ischemia reperfusion injury | |
| Verbist et al. | A role for IL-15 in the migration of effector CD8 T cells to the lung airways following influenza infection | |
| Mathä et al. | Migration of lung resident group 2 innate lymphoid cells link allergic lung inflammation and liver immunity | |
| Yao et al. | Downregulation of T-bet/GATA-3 ratio induced by IL-11 treatment is responsible for Th1/Th2 balance restoration in human immune thrombocytopenic purpura (ITP) | |
| Liu et al. | Over-expression of CXCR4 on mesenchymal stem cells protect against experimental colitis via immunomodulatory functions in impaired tissue | |
| Moffat et al. | Granzyme A expression reveals distinct cytolytic CTL subsets following influenza A virus infection | |
| Mendes et al. | Proteostasis in dendritic cells is controlled by the PERK signaling axis independently of ATF4 | |
| Lee et al. | Selective expansion of tregs using the IL-2 cytokine antibody complex does not reverse established alopecia areata in C3H/HeJ mice | |
| Cantoni et al. | Role of NK cells in immunotherapy and virotherapy of solid tumors | |
| Zheng et al. | Phenotypic and functional characteristics of a novel influenza virus hemagglutinin-specific memory NK cell | |
| Abboud et al. | Transcription factor Bcl11b controls effector and memory CD8 T cell fate decision and function during poxvirus infection | |
| Sun et al. | NLRC5 deficiency has a moderate impact on immunodominant CD 8+ T‐cell responses during rotavirus infection of adult mice | |
| Zhou et al. | Protective effect of trichostatin A on CD19+ CD5+ CD1d high regulatory B cells in heart transplantation | |
| Rüterbusch et al. | Allergen exposure functionally alters influenza-specific CD4+ Th1 memory cells in the lung | |
| Lam et al. | Targeting mesenchymal stem cell therapy for severe pneumonia patients | |
| Sturm et al. | Functional hyper-IL-6 from vaccinia virus-colonized tumors triggers platelet formation and helps to alleviate toxicity of mitomycin C enhanced virus therapy |